Hematology

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee again voted in favor of the risk-benefit of bluebird bio's gene therapy candidate.

Review top news and interview highlights from the week ending June 10, 2022.

Three of 6 patients have an ongoing response.

The vice-chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center discussed positive data seen with tisa-cel, liso-cel, ide-cel, cilta-cel, and brexu-cel.

Data from a phase 1/2a study showed notable response rates in patients who had received a median of 5 prior lines of therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chimeric antigen receptor-modified autologous T cells targeting CLDN18.2 had a manageable safety/tolerability profile and promising efficacy.

100% overall response and complete response rates were seen in patients treated with prior CD19 CAR T-cell therapy.

Jason Westin, MD, FACP, leader, DLBCL research team, MD Anderson Cancer Center, discussed results from the ZUMA-7 trial at ASCO 2022.

The findings suggest that less disadvantaged patients with high disease burden may have greater ability to advocate for CAR T-cell therapy.

69% of patients followed up for at least 1 year continue to have an ongoing response.

Niels van de Donk, MD, PhD, professor, Amsterdam University Medical Centers, discussed positive findings from cohort B of the CARTITUDE-2 study.

Regardless of bone marrow cellularity, bone marrow minimal residual disease (MRD) negativity at month 1 correlated with deep response and prolonged PFS.

Melissa Alsina, MD, gave a talk on novel CAR therapies, targets, and approaches at the 2022 ASCO meeting.

Cohort A of the CARTITUDE-2 study is evaluating cilta-cel safety and efficacy in patients with multiple myeloma who received 1 to 3 prior lines of therapy.

The associate professor of medicine at Medical College of Wisconsin discussed advantages of the ARC-SparX platform.

High response rates were seen in patients that would not meet ZUMA-2 eligibility criteria.

No differences were found in overall survival and progression free survival across races.

Review top news and interview highlights from the week ending June 3, 2022.

A recent meta-analysis reviewed data across 146 patients in 9 clinical trials.

Relma-cel was previously approved in China in September 2021 for the treatment of B-cell non-Hodgkin lymphoma.

Beti-cel was rated a B+ for lingering questions about durability and unknown risks.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

BioMarin now expects to file in September 2022 instead of June.

Treated patients had significant improvements in fatigue and lymphoma symptoms.

The approval was based on data from the phase 2 ELARA clinical trial, in which a complete response of more than 65% was observed.

The director of the Center for Multiple Myeloma and Mass Gen discussed unmet needs with CAR T-cell therapy in multiple myeloma.

Review top news and interview highlights from the week ending May 27, 2022.

The chief executive officer of Ring Therapeutics, Tuyen Ong, MD, discussed the potential of anellovirus vectors for use in gene therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.